retatrutide fda approval status eli lilly approves this year? Predictions & Odds 2026 Retatrutide approval: FDA status, clinical

First, we emulated two cardiovascular outcome trials, SUSTAIN-6 (semaglutide versus sitagliptin as placebo proxy) and SURPASS-CVOT (tirzepatide versus dulaglutide), to benchmark and critically evaluate our design, data and analytic framework

And the injection spacing is flexible enough to accommodate travel or schedule changes

Phase 2 first patient dosed January 2026

The Valuation of Expanded Indications The clinical data regarding retatrutides impact on obstructive sleep apnea and osteoarthritis pain severity introduces a new narrative for Eli Lilly

This is why kidney protection has become a major focus of diabetes care worldwide